Published August 17, 2026Updated October 30, 2026

Ozempic vs Wegovy Price: Why One Costs More

One molecule, semaglutide, sold under two names at different doses and approved by the FDA for different things. We explain the pricing arbitrage and which to choose.

By Ruth Calder, Enforcement Editor

Our methodology sets out how these guides get researched and kept current.

Looking for a provider? Our 2026 comparison of the leading GLP-1 telehealth sellers is a click away.

Best Semaglutide Providers →

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

Ozempic and Wegovy are the same drug. Both contain semaglutide, the molecule is identical, and the same manufacturer (Novo Nordisk) makes both in the same facilities. So why are they two products with two names, two prices, two FDA approvals, and two different insurance coverage rules?

The answer is regulatory and commercial. Once you understand it, you can spot the pricing arbitrage that millions of patients miss. Below we cover how the two brands differ, why one is often much cheaper than the other depending on your situation, and how to choose between them in 2026.

If you have already settled on compounded semaglutide and only need a seller, go straight to our best semaglutide providers list.

Key Takeaways

  • Same active ingredient (semaglutide), same manufacturer (Novo Nordisk).
  • Different FDA approvals: Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management.
  • Different doses: Ozempic tops out at 2.0 mg weekly. Wegovy's usual maintenance dose is 2.4 mg, and its label now allows up to 7.2 mg; Wegovy also comes as a daily tablet.
  • Different list prices: Ozempic is ~$1,028/month, Wegovy is ~$1,349/month. Both are also sold for cash through NovoCare Pharmacy from $349/month (Wegovy pill from $149).
  • Insurance treats them very differently: Ozempic is covered for diabetes; Wegovy coverage for obesity is far more limited.
  • Compounded semaglutide bypasses both and is widely available at $129–$249/month.

The Same Molecule, Two Products

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone your gut releases after meals. It binds to GLP-1 receptors in the brain to suppress appetite, slows gastric emptying so you feel full longer, and improves insulin sensitivity. The science is identical regardless of which brand you take.

Why are there two brands? Because Novo Nordisk pursued two separate FDA approvals for semaglutide, one for diabetes (Ozempic, approved 2017) and one for obesity (Wegovy, approved 2021). Each approval requires its own clinical trial program, labeling and pricing strategy, and, most important for patients, its own insurance reimbursement codes.

This is a common pharmaceutical strategy. The active ingredient is the same; the regulatory packaging and the marketing are different. (For the parallel case in tirzepatide, see Mounjaro vs Zepbound.)

What's Actually Different

1. Dosing

This is the only meaningful clinical difference. Ozempic and Wegovy use the same titration schedule for the first 12 weeks, then diverge:

1. Dosing
WeekOzempic doseWegovy dose
1–40.25 mg0.25 mg
5–80.5 mg0.5 mg
9–121.0 mg1.0 mg
13–161.0 mg1.7 mg
17+up to 2.0 mg2.4 mg (usual maintenance; up to 7.2 mg)

Wegovy's higher maintenance dose (2.4 mg) was the dose tested in the STEP-1 obesity trial that produced 14.9% weight loss. Ozempic was originally tested at lower diabetes-focused doses, though Novo Nordisk later added a 2.0 mg option for diabetes patients who needed more glycemic control. Wegovy's label has since added a 7.2 mg dose (Wegovy HD) for adults still short of their goal after four or more weeks on 2.4 mg.

In practice, at the usual 2.4 mg maintenance dose Wegovy gives you ~20% more semaglutide per dose than Ozempic's 2.0 mg maximum. For weight loss, that matters. For diabetes control, the difference is small.

2. FDA Indication

  • Ozempic carries three approvals, all confined to adults with type 2 diabetes: glycemic control; where heart disease is already known, fewer heart attacks, strokes and cardiovascular deaths; and, in people who also have chronic kidney disease, a lower risk of lasting kidney-function decline, kidney failure and cardiovascular death.
  • Wegovy carries three. The first is long-term weight management, open to adults at BMI ≥30, or at BMI ≥27 with a weight-related comorbidity. The second arrived in 2024 on the strength of the SELECT trial: in adults who have both obesity or overweight and established cardiovascular disease, it lowers the odds of a heart attack, stroke or cardiovascular death. The third covers adults with noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) and moderate to advanced liver fibrosis, under accelerated approval.

The indication matters most when the claim reaches the insurer. Nothing stops a doctor from writing Ozempic off-label for weight loss, but without a documented diabetes diagnosis most insurers refuse to pay for it.

3. Pricing

List prices (no insurance, no coupon) in 2026:

  • Ozempic: ~$1,028/month
  • Wegovy: ~$1,349/month

The Wegovy premium reflects the higher maintenance dose plus Novo Nordisk's pricing strategy for the obesity market, which has different payer dynamics than diabetes. In real life almost no one pays the full list price; what you pay depends on your insurance and which manufacturer programs you qualify for. Without coverage, Novo Nordisk sells both for cash through NovoCare Pharmacy: Ozempic runs $349 a month, or $499 on 2 mg; the Wegovy pen is also $349, or $399 on 7.2 mg; and the Wegovy pill starts at $149. Our manufacturer coupons guide has the full terms.

Telehealth sellers list the two brands differently. TrimRx lists Ozempic and GobyMeds lists Wegovy, while Wellorithm and myRocky list both. Concierge MD LA lists Ozempic and Wegovy alongside Mounjaro and Zepbound. Vital Edge stocks both brands as well as Rybelsus.

Several bill for the care rather than the drug. Calibrate Health charges a membership program fee, with the medication on your insurance copay. Measured sells a brand-name care membership with Wegovy bought separately, and QuickMD charges a per-visit consultation fee for a brand prescription.

4. Insurance Coverage

Coverage is where the two brands really diverge. As of 2026:

  • Ozempic is covered by virtually every major insurer for type 2 diabetes patients; with commercial coverage, Novo Nordisk's savings card can bring the co-pay down to as little as $25/month.
  • Wegovy is covered by *some* commercial insurers for obesity, but coverage is patchy and often comes with strict prior authorization (BMI requirements, prior weight-loss program documentation, etc.). Part D plans may cover Wegovy for its cardiovascular indication. For weight management, Medicare Part D patients who qualify can get Wegovy for $50/month under the Medicare GLP-1 Bridge, a temporary program that started in July 2026 and is set to end with 2027.

This insurance gap is why the off-label Ozempic-for-weight-loss market exploded in 2022–2024. Patients without a diabetes diagnosis frequently asked their doctors to write off-label Ozempic prescriptions because insurance was more likely to cover it.

For a complete look at the insurance landscape, see our Cost & Insurance pillar guide.

The Pricing Arbitrage (and Why It Mostly Disappeared)

From 2021 to 2024, there was a clear arbitrage: get an off-label Ozempic prescription, pay your diabetes copay, and use the lower-dose Ozempic for weight loss. This worked because:

  1. Insurance covered Ozempic but not Wegovy.
  2. Both drugs are semaglutide.
  3. A 1.0 mg or 2.0 mg Ozempic dose still produced meaningful weight loss.

This loophole is largely closed in 2026 for three reasons:

  1. Insurance audits caught up. PBMs now require diabetes documentation (HbA1c lab results) for Ozempic claims.
  2. Novo Nordisk supply allocation prioritized Wegovy as the obesity-indicated brand, making off-label Ozempic harder to get filled.
  3. Compounded semaglutide became dramatically cheaper than either brand, with no insurance friction.

Today the price gap that matters is between brand-name and compounded semaglutide.

Compounded Semaglutide: The Real Cheat Code

Compounded semaglutide is made by state-licensed 503A compounding pharmacies and dispensed through telehealth providers. FDA says 503B outsourcing facilities may not compound it from bulk now that the shortage is over. It has the same active ingredient at a fraction of the price:

Compounded Semaglutide: The Real Cheat Code
SourceMonthly cost (typical)
Wegovy (list price)$1,349
Ozempic (list price)$1,028
Wegovy pen (NovoCare self-pay)$349
Wegovy pill (NovoCare self-pay)$149–$299
Compounded semaglutide (telehealth)$129–$249

Before choosing compounded, understand the safety considerations. We cover them in detail in our guide on compounded semaglutide safety. In short, stick to providers who name a 503A pharmacy you can find in your state board of pharmacy's license database, and ask any seller claiming "503B-made" semaglutide how that is allowed. Verify with LegitScript before signing up.

Our best GLP-1 providers ranking scores providers on what they publish, including whether they name their pharmacy. Top picks for compounded semaglutide in 2026:

  • CoreAge Rx: $79/month at every dose
  • Henry Meds: $297/month, established player with strong support

Use our GLP-1 savings calculator to compare your specific situation against both.

Side Effects: Identical

Because it's the same molecule, the side effect profile is identical between Ozempic, Wegovy, and compounded semaglutide. In the 1–4 weeks following any dose increase, expect nausea, constipation, headache, fatigue, and vomiting now and then. Serious adverse events (pancreatitis, gallbladder disease, kidney injury) are rare but real.

For a complete management guide, read our deep dive on managing semaglutide side effects.

Bottom Line

Ozempic and Wegovy are the same drug at different doses with different FDA labels and very different insurance treatment. With type 2 diabetes the decision is easy: Ozempic gives you coverage, an appropriate dose and a cost you can live with. If you don't have diabetes and are using a GLP-1 for weight management, Wegovy is the on-label option; without insurance, Novo Nordisk's cash price starts at $349/month for the pen and $149/month for the pill.

For most weight-loss patients in 2026, the practical answer is *neither brand*. Compounded semaglutide through a reputable telehealth provider costs 80–90% less than Wegovy's list price and uses the same molecule. Brand-name Wegovy makes sense mainly if your insurance covers it at a low co-pay or you specifically need the FDA-approved formulation for medical-legal reasons (some employers, some specific patient profiles).

For more on the broader semaglutide picture, see our full semaglutide drug guide. For the tirzepatide alternative, see Semaglutide vs Tirzepatide.

Sources & methodology — as of October 2026
  1. 1.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  2. 2.STEP 2 Trial — Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity and Type 2 Diabetes (Davies M et al.)— The Lancet.PMID: 33667417.
  3. 3.SUSTAIN-6 Trial — Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (Marso SP et al.)— New England Journal of Medicine.PMID: 27633186.
  4. 4.SELECT Trial — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (Lincoff AM et al.)— New England Journal of Medicine.PMID: 37952131.
  5. 5.STEP 4 Trial — Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (Rubino D et al.)— JAMA.PMID: 33755728.
  6. 6.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  7. 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.

Ready to compare GLP-1 providers?

Trust, support, availability, the medications carried and what they cost — we rank every major telehealth seller on all five, and refresh it each quarter. Nothing padded.

Best Semaglutide Providers →

Read our methodology · affiliate disclosure · about us